MediWound

Company Overview

Snapshot

Founded in January 2000, MediWound operates with 51–200 employees and has raised a total of $198.72 million across 8 funding rounds from 10 investors. In July 2024, the company secured a strategic investment from Mölnlycke Health Care.

Business overview

MediWound is a global biotechnology company focused on pioneering enzymatic, non-surgical therapies for tissue repair. The company's core product, NexoBrid, is an FDA-approved biologic for the enzymatic removal of eschar in thermal burns, marketed across the United States, European Union, Japan, and other international markets. Additionally, MediWound is developing EscharEx, an investigational therapy for chronic wound debridement, aiming to set a new standard in wound management. The company operates within the Health Tech & Life Sciences sector, specifically in Pharmaceuticals, targeting healthcare providers and patients.

Strategic signal

In November 2025, MediWound successfully completed the commissioning of its expanded GMP manufacturing facility for NexoBrid. This development signals the company's commitment to scaling production and meeting growing demand for its enzymatic burn treatment, indicating a strong operational trajectory and readiness for broader market penetration.

Company Intelligence Q&A

What was a significant recent financial event for MediWound?

In September 2025, MediWound announced a $30 million registered direct offering of ordinary shares.

What strategic partnership did MediWound announce in November 2023?

In November 2023, MediWound announced a collaboration with PolyMedics Innovations (PMI) for NexoBrid® distribution in Europe, expanding its market reach.

What was the outcome of MediWound's Q3 2024 earnings report?

In November 2024, MediWound reported its Third Quarter 2024 financial results, missing revenue estimates and reporting a Q3 loss.

What was a key development for NexoBrid® in September 2025?

In September 2025, MediWound expanded its global reach with marketing approval of NexoBrid® in Australia.

What collaboration did MediWound announce for its EscharEx® Phase III study?

In October 2023, MediWound announced a collaboration with 3M on the EscharEx® Phase III study, advancing the development of its chronic wound treatment.